Overall Index Performance and Market Breadth

The large-cap index, represented by the BSE 100, has shown signs of pressure, slipping 0.75% on 23 April 2026. This decline extends a recent trend, with the index down 0.51% over the last five trading days. Market breadth within this segment remains weak, as 26 stocks advanced against 73 decliners, resulting in an advance-decline ratio of just 0.36x. This skew towards declining stocks highlights the cautious sentiment prevailing among investors in the large-cap space.

Top and Bottom Performers

Among the large-cap constituents, Dr Reddy's Laboratories emerged as the best performer, delivering a notable return of 7.81%. The pharmaceutical giant's resilience amid broader market softness underscores its defensive qualities and investor preference for stable earnings growth in uncertain times.

Conversely, Havells India was the worst performer in the segment, registering a decline of 6.34%. The electrical equipment maker's underperformance may be attributed to concerns over cyclical demand pressures and margin headwinds, which have weighed on investor confidence.

Defensive Versus Cyclical Trends

The divergence between defensive and cyclical stocks is increasingly evident. Defensive sectors such as pharmaceuticals and banking have attracted buying interest, as reflected in the strong showing of Dr Reddy's Laboratories and the recent upgrades in banking stocks. Meanwhile, cyclical names, including Havells India, have faced selling pressure amid worries about slowing economic activity and input cost inflation.

Technical Upgrades and Downgrades

Several large-cap stocks have seen recent upgrades in their technical scores, signalling improved market sentiment. Notably, Axis Bank has been upgraded from mildly bullish to bullish, while Indian Oil Corporation (IOCL) moved from sideways to mildly bullish. Samvardhana Motherson also received a mild bullish upgrade. Interestingly, SBI and Lupin were downgraded slightly from bullish to mildly bullish, indicating some moderation in momentum but still maintaining positive technical bias.

Fundamental Rating Changes

From a fundamental perspective, both Canara Bank and SBI have been upgraded from Hold to Buy ratings, reflecting improved earnings outlooks and asset quality trends. These upgrades align with the broader preference for defensive large caps amid market volatility.

Upcoming Quarterly Results to Watch

Investor focus will soon shift to a series of large-cap earnings announcements scheduled over the next few days. Key results include Reliance Industries, Shriram Finance, and IndusInd Bank on 24 April 2026, followed by Axis Bank and IDFC First Bank on 25 April 2026. These earnings releases are expected to provide fresh insights into sectoral trends and corporate earnings momentum, potentially influencing large-cap index direction in the near term.

Sectoral Implications and Investor Strategy

The recent performance and technical upgrades suggest a cautious but selective approach among investors. Defensive sectors such as banking and pharmaceuticals are favoured for their relative stability and earnings visibility. The upgrades in Axis Bank and Canara Bank ratings reinforce this trend, signalling confidence in their balance sheets and growth prospects.

Meanwhile, cyclical sectors remain under pressure, with Havells India’s sharp decline exemplifying the challenges faced by companies exposed to discretionary spending and industrial demand. Investors may prefer to underweight such names until clearer signs of economic recovery emerge.

Market Outlook for Large Caps

Given the current environment, the large-cap segment is likely to remain volatile in the short term. The modest decline in the BSE 100 index and weak breadth indicate that selling pressure is broad-based, though pockets of strength persist in defensive stocks. Monitoring upcoming earnings and technical developments will be crucial for investors seeking to navigate this mixed landscape.

Conclusion

The large-cap segment continues to reflect a market grappling with uncertainty and sectoral divergence. Defensive stocks, particularly in banking and pharmaceuticals, have demonstrated resilience and attracted upgrades both technically and fundamentally. Conversely, cyclical names face headwinds amid economic concerns and margin pressures. Investors are advised to maintain a balanced approach, favouring quality large caps with stable earnings and strong technical setups while remaining cautious on more volatile cyclical exposures. The forthcoming earnings season will be pivotal in shaping the near-term trajectory of the large-cap index.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today